The Arrowhead Pharmaceuticals facility is a drug manufacturing and laboratory campus at the Verona Technology Park in Wisconsin. The company has since obtained a full certificate of occupancy for the laboratory, office and manufacturing spaces, and the campus has grown to nearly 300,000 square feet in total.
Verona Campus Part of Wisconsin’s Growing Manufacturing Investment
The company is now completing commissioning and validation work needed to release commercial drug substance from the site. Arrowhead received up to $16 million in incentives from the city of Verona and $2.5 million in state tax credits toward the project. A similar wave of investment is unfolding nearby, where CHS is building a $700 million soybean processing facility near Evansville, a project Governor Tony Evers has also championed as a boost for Wisconsin’s economy.
Project Overview
- Project Name: Arrowhead Pharmaceuticals Facility, Verona Technology Park
- Location: Verona, Wisconsin, Dane County
- Owner and Operator: Arrowhead Pharmaceuticals
- Project Value: Originally estimated at $200 million to $250 million (the Wisconsin Economic Development Corporation cited a $220 million expansion at groundbreaking)
- Site Area: 13 acres in the Verona Technology Park
- Building Scope: Drug manufacturing, laboratory and office space now totaling nearly 300,000 square feet
- Regulatory Milestone: Full certificate of occupancy obtained in August 2024
- Current Status: Completing commissioning, qualification and validation of GMP drug substance manufacturing capabilities
- Incentives: Up to $16 million in tax increment financing from the city of Verona; up to $2.5 million in tax credits from the Wisconsin Economic Development Corporation
- Jobs: Approximately 250 new positions in the Madison area
Project Team
- Owner and Operator: Arrowhead Pharmaceuticals
- Architect: Eppstein Uhen Architects
- Project Management and Engineering: DPS Group
- Civil Engineering: D’Onofrio Kottke & Associates
- General Contractor: Vogel Bros. Building Co.
- Public Body: City of Verona, Wisconsin
- Financier: Wisconsin Economic Development Corporation
Reported 12th January 2022: Construction will soon commence on a $250 million Arrowhead Pharmaceuticals Facility in Verona. The California-based Arrowhead Pharmaceuticals Inc., intends to build this facility on a 13 acre-site, which the company recently purchased at the Verona Technology Park.
This new 255,000-sf Arrowhead Pharmaceuticals Facility will be the company’s second pharmaceutical complex to be built in Wisconsin, consisting of a 140,000-square-foot drug manufacturing facility and a 115,000-square-foot laboratory. But unlike the company’s other facilities, which include its Pasadena HQ, the Madison and San Diego facilities; this new campus in Verona will be completely devoted to drug manufacturing and Arrowhead says this signifies that it’s progressing from the research and development phase to the commercialization of its medication treatments.
Also Read Converting Assembly Plant into Budd Bioworks Biomanufacturing Plant
New Arrowhead Pharmaceuticals Facility brings 250 jobs to Verona
At the new Arrowhead Pharmaceuticals Facility in Verona, the company will focus solely on developing a variety of medications used for treating a wide range of diseases, through the use of its RNA technology. According to the company, this RNA technology silences the genes that propagate the diseases and the process is referred to as TRiM. Robert Tiegen, an Arrowhead associate counsel, also mentioned that this expansion project would create up to 250 new jobs in Madison, with a mix of positions that pay upto five times the minimum wage in the area. Construction is scheduled to begin by winter, with the opening set for the end of 2023.
Christopher Anzalone, the company’s chief executive gave more insights on the new Arrowhead Pharmaceuticals Facility and how this new development would support the company’s growing pipeline and positions. Anzalone also mentioned that this new pharmaceutical facility in Verona would help the company make further advancements in its production process, especially on a commercial level for the company’s TRiM-enabled drug candidates. He said Arrowhead acknowledges this as a strong competitive advantage, as the company continues advancing towards its main goal of commercializing its rapidly progressing clinical candidates. Anzalone added, “Arrowhead’s pipeline of what we believe are industry-leading investigational RNAi medicines continues to expand rapidly.”
Leave a Reply